携带常见功能性IGF1R变异的子宫内膜异位症或多囊卵巢综合征女性心血管风险降低
基于护士健康研究2(NHS2)的回顾性队列研究,纳入1989年入组的116430名女性并随访至2015年,分析IGF1R SNP rs2016347 T等位基因与子宫内膜异位症或多囊卵巢综合征女性未来心血管疾病风险的关系。携带T等位基因的子宫内膜异位症女性在1989年前队列中CVD风险降低(HR 0.48),多囊卵巢综合征女性在1989年后队列中高血压风险降低(HR 0.44)。
要点
- 子宫内膜异位症携带T等位基因者1989年前队列CVD风险降低(HR 0.48)。
- 多囊卵巢综合征携带T等位基因者1989年后队列高血压风险降低(HR 0.44)。
- 无子宫内膜异位症或多囊卵巢综合征女性中基因型对风险无影响。
核心结论
- 携带IGF1R SNP rs2016347 T等位基因的子宫内膜异位症或多囊卵巢综合征女性未来发生心血管疾病及相关风险因素的风险降低,且风险降低取决于队列时期。
研究设计与样本
- 回顾性队列研究,基于护士健康研究2(NHS2),1989年入组116430名25至42岁女性注册护士,随访至2015年。
- 研究人群整体分析,并分为入组前(1989年前)和入组后(1989年后)暴露队列。
- 排除缺失协变量者9599名(8.2%)。
- 数据分析时间为2020年11月至2021年6月。
主要发现
- 无子宫内膜异位症或多囊卵巢综合征女性整体上基因型对两个队列的风险均无影响。
- 子宫内膜异位症携带T等位基因者1989年前队列CVD风险降低(HR 0.48;95%CI 0.27-0.86;P=0.02),高血压风险降低(HR 0.80;95%CI 0.66-0.97;P=0.03)。
- 子宫内膜异位症携带T等位基因者1989年后队列高胆固醇血症风险降低(HR 0.76;95%CI 0.62-0.94;P=0.01)。
- 多囊卵巢综合征1989年后队列携带T等位基因者高血压风险降低(HR 0.44;95%CI 0.27-0.73;P=0.002),高胆固醇血症风险降低(HR 0.62;95%CI 0.40-0.95;P=0.03)。
局限性
- 缺乏特定子宫内膜异位症病灶位置或疾病分期数据,以及多囊卵巢综合征表型数据。
- 缺乏除口服避孕药以外的全身性药物治疗数据,这些治疗可能混杂结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is the increased future cardiovascular risk seen in women with endometriosis or polycystic ovary syndrome (PCOS) mitigated by functional insulin-like growth factor-1 receptor (IGF1R) single-nucleotide polymorphism (SNP) rs2016347 as previously shown in women with hypertensive disorders of pregnancy? SUMMARY ANSWER: This cohort study found that women with endometriosis or PCOS who carry a T allele of IGF1R SNP rs2016347 had a reduced future risk of developing cardiovascular disease (CVD) and associated risk factors, with risk reduction dependent on cohort era. WHAT IS KNOWN ALREADY: Women with endometriosis or PCOS have been shown to have an increased future risk of CVD and associated risk factors with limited predictive ability. STUDY DESIGN, SIZE, DURATION: This retrospective cohort study took place in the Nurses' Health Study 2 (NHS2), which enrolled 116 430 participants in 1989 who were followed through 2015. The study population was analyzed in its entirety, and subdivided into entry (pre-1989) and after entry (post-1989) exposure cohorts. All NHS2 participants were eligible for inclusion in the study, 9599 (8.2%) were excluded for missing covariates. PARTICIPANTS/MATERIALS, SETTING, METHODS: The NHS2 enrolled female registered nurses from 14 different states who ranged in age from 25 to 42 years at study entry. Data were collected from entry and biennial questionnaires, and analysis conducted from November 2020 to June 2021. Cox proportional hazard models were used to assess risk of CVD, hypertension (HTN), hypercholesterolemia (HC) and type 2 diabetes, both with and without genotyping for rs2016347. MAIN RESULTS AND THE ROLE OF CHANCE: While women without endometriosis or PCOS, as a whole, demonstrated no impact of genotype on risk in either cohort, women with endometriosis carrying a T allele had a lower risk of CVD (hazard ratio (HR), 0.48; 95% CI, 0.27-0.86, P = 0.02) and HTN (HR, 0.80; 95% CI, 0.66-0.97, P = 0.03) in the pre-1989 cohort, while those in the post-1989 cohort had a decrease in risk for HC (HR, 0.76; 95% CI, 0.62-0.94, P = 0.01). Women with PCOS in the post-1989 cohort showed a significant protective impact of the T allele on HTN (HR, 0.44; 95% CI, 0.27-0.73, P = 0.002) and HC (HR, 0.62; 95% CI, 0.40-0.95, P = 0.03). LIMITATIONS, REASONS FOR CAUTION: Data on specific endometriosis lesion locations or disease stage, as well as on PCOS phenotypes were lacking. In addition, data on systemic medical treatments beyond the use of oral contraceptives were missing, and these treatments may have confounded the results. WIDER IMPLICATIONS OF THE FINDINGS: These findings implicate systemic dysregulation of the insulin-like growth factor-1 axis in the development of HTN, HC and clinical CVD in endometriosis and PCOS, suggesting a common underlying pathogenetic mechanism. STUDY FUNDING/COMPETING INTEREST(S): The NHS2 infrastructure for questionnaire data collection was supported by National Institute of Health (NIH) grant U01CA176726. This work was also supported in part by NIH and National Cancer Institute grant U24CA210990; as well, research effort and publication costs were supported by the Elizabeth MA Stevens donor funds provided to the Buck Institute for Research on Aging. The authors declare they have no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Powell MJ, Fuller S, Gunderson EP, et al. Reduced cardiovascular risks in women with endometriosis or polycystic ovary syndrome carrying a common functional IGF1R variant. Hum Reprod. 2022. PMID: 35362533. doi:10.1093/humrep/deac059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。